Results 161 to 170 of about 99,558 (321)
U-health Expert System with Statistical Neural Network [PDF]
Byoung-Ho Song+2 more
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
JEL Ratio Test for Independence of Time to Failure and Cause of Failure in Competing Risks Data
In the present article, we propose a Jackknife empirical likelihood (JEL) ratio test for testing the independence of time to failure and cause of failure in competing risks data. We use the U-statistics theory to derive the JEL ratio test. The asymptotic
Narayanan Sreelakshmy+1 more
doaj +1 more source
APPLAUSE: Automatic Prediction of PLAcental health via U-net Segmentation and statistical Evaluation [PDF]
Maximilian Pietsch+7 more
openalex +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
An intercomparison of statistical downscaling methods used for water resource assessments in the
E. D. Gutmann+6 more
openalex +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Drop-Weight Impact Test on U-Shape Concrete Specimens with Statistical and Regression Analyses [PDF]
Xue-chao Zhu, Han Zhu, Haoran Li
openalex +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
U-statistic with side information. [PDF]
Yuan A, He W, Wang B, Qin G.
europepmc +1 more source